Discovery & development of monoclonal antibodies and other biologic therapeutics relies heavily on analytical methods to capture molecular attributes, assess development risks, and optimize complex drug substance mixtures. With many methods to choose from, NMR spectroscopy is uniquely sensitive to low affinity transient interactions, lowly populated states; able to simultaneously detect proteins, small molecule excipients and their interactions. We will present several case studies, demonstrating NMR impact on development programs.
